title: No adverse effect of ABVD chemotherapy in a patient with chronic hepatitis C and Hodgkin's disease.
abstract: There is insufficient information on the effects of chemotherapy protocols for Hodgkin's disease (HD) and the course of coexisting hepatitis C virus (HCV) infection. A single literature case reported a patient with HD who developed fulminant hepatitis and hepatic coma after receiving chemotherapy. The case described here is of a female patient previously exposed to prolonged war stress, complicated by intravenous drug abuse and chronic hepatitis C. One year after diagnosis of HCV infection she was diagnosed with HD (nodular sclerosis type II, clinical stage IIIB). The patient received six cycles of ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) resulting in complete remission of HD. There was no hepatitis flare either during or after chemotherapy. In conclusion, there were no adverse effects of the ABVD regimen on the course of HCV infection in this patient who was successfully treated for HD. Because concurrent HCV infection and HD is extremely rare, we discuss here the possibility of the synergistic contribution of chronic war stress and hepatitis C infection in the pathogenesis of HD.
authors.affiliation: Division of Hematology, Department of Internal Medicine, Dubrava University Hospital, Zagreb, Croatia. vpejsa@kbd.hr
authors.forename: Vlatko
authors.initials: V
authors.lastname: Pejsa
authors.forename: Ivica
authors.initials: I
authors.lastname: Grgurević
authors.forename: Milan
authors.initials: M
authors.lastname: Kujundzić
authors.forename: Marko
authors.initials: M
authors.lastname: Martinović
authors.forename: Vladimir
authors.initials: V
authors.lastname: Stancić
authors.forename: Kyle
authors.initials: K
authors.lastname: Donley
authors.forename: Steven
authors.initials: S
authors.lastname: Pavletic
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D003130:Combat Disorders / Q000150:complications; D017523:Croatia; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000150:complications*; D006689:Hodgkin Disease / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology; D008111:Liver Function Tests; D009367:Neoplasm Staging; D012074:Remission Induction; D015819:Substance Abuse, Intravenous / Q000150:complications; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin